|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
29,730,000 |
Market
Cap: |
1.43(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$26.52 - $75.32 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 20 |
Insider 3/6 Months : 20.6 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Gemeni Therapeutics is a clinical-stage precision medicine company developing therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). Co.'s lead product candidate, GEM103, is a recombinant form of the human complement factor H protein and is designed to address complement hyperactivity and overall dysregulation caused by loss of function mutations thus restoring retinal health in patients with AMD.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
388,891 |
388,891 |
1,041,066 |
Total Buy Value |
$0 |
$14,000,076 |
$14,000,076 |
$29,000,101 |
Total People Bought |
0 |
3 |
3 |
4 |
Total Buy Transactions |
0 |
3 |
3 |
6 |
Total Shares Sold |
5,359 |
10,077 |
1,816,761 |
3,929,683 |
Total Sell Value |
$262,142 |
$419,912 |
$108,633,360 |
$210,494,186 |
Total People Sold |
2 |
2 |
9 |
13 |
Total Sell Transactions |
5 |
8 |
40 |
59 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Khara Rahul |
General Counsel |
|
2023-11-14 |
4 |
AS |
$50.53 |
$248,012 |
D/D |
(4,900) |
0 |
|
17% |
|
Khara Rahul |
General Counsel |
|
2023-11-14 |
4 |
OE |
$14.69 |
$71,981 |
D/D |
4,900 |
4,900 |
|
- |
|
Khara Rahul |
General Counsel |
|
2023-11-03 |
4 |
AS |
$50.00 |
$5,000 |
D/D |
(100) |
0 |
|
27% |
|
Khara Rahul |
General Counsel |
|
2023-11-03 |
4 |
OE |
$14.69 |
$1,469 |
D/D |
100 |
100 |
|
- |
|
Atlas Venture Associates X, Llc |
10% Owner |
|
2023-09-16 |
4 |
S |
$53.22 |
$112,560 |
D/D |
(2,115) |
1,593,785 |
|
-23% |
|
Atlas Venture Associates X, Llc |
10% Owner |
|
2023-09-15 |
4 |
S |
$53.16 |
$13,869,125 |
D/D |
(260,894) |
1,595,900 |
|
-19% |
|
Atlas Venture Associates X, Llc |
10% Owner |
|
2023-09-14 |
4 |
S |
$53.05 |
$5,010,042 |
D/D |
(94,440) |
1,856,794 |
|
-17% |
|
Bryce Joanne |
Chief Financial Officer |
|
2023-09-11 |
4 |
OE |
$9.86 |
$24,650 |
D/D |
2,500 |
3,760 |
|
- |
|
Bryce Joanne |
Chief Financial Officer |
|
2023-09-01 |
4 |
AS |
$52.99 |
$52,990 |
D/D |
(1,000) |
1,260 |
|
18% |
|
Bryce Joanne |
Chief Financial Officer |
|
2023-09-01 |
4 |
OE |
$2.65 |
$2,650 |
D/D |
1,000 |
2,260 |
|
- |
|
Savage William Jacob |
Chief Medical Officer |
|
2023-08-21 |
4 |
OE |
$2.65 |
$7,950 |
D/D |
3,000 |
3,000 |
|
- |
|
Bitterman Kevin |
Director |
|
2023-08-15 |
4 |
S |
$52.40 |
$3,821,584 |
I/I |
(72,931) |
882,224 |
|
-8% |
|
Savage William Jacob |
Chief Medical Officer |
|
2023-08-15 |
4 |
AS |
$52.27 |
$406,235 |
D/D |
(7,672) |
0 |
|
8% |
|
Atlas Venture Associates Opportunity I, Llc |
10% Owner |
|
2023-08-15 |
4 |
S |
$52.40 |
$3,821,584 |
I/I |
(72,931) |
882,224 |
|
-8% |
|
Atlas Venture Associates Opportunity I, Llc |
10% Owner |
|
2023-08-15 |
4 |
S |
$52.40 |
$5,820,016 |
D/D |
(111,069) |
1,951,234 |
|
-8% |
|
Atlas Venture Associates Opportunity I, Llc |
10% Owner |
|
2023-08-14 |
4 |
S |
$52.00 |
$9,203,600 |
D/D |
(175,000) |
2,062,303 |
|
-9% |
|
Savage William Jacob |
Chief Medical Officer |
|
2023-08-09 |
4 |
AS |
$48.90 |
$412,064 |
D/D |
(8,269) |
7,672 |
|
17% |
|
Bryce Joanne |
Chief Financial Officer |
|
2023-08-01 |
4 |
AS |
$49.63 |
$225,633 |
D/D |
(4,521) |
1,260 |
|
14% |
|
Bryce Joanne |
Chief Financial Officer |
|
2023-08-01 |
4 |
OE |
$1.01 |
$4,566 |
D/D |
4,521 |
5,781 |
|
- |
|
Macdonald Brian Richard |
Chief Innovation Officer |
|
2023-06-30 |
4 |
S |
$46.76 |
$28,058 |
D/D |
(600) |
12,276 |
|
-11% |
|
Macdonald Brian Richard |
Chief Innovation Officer |
|
2023-06-30 |
4 |
AS |
$44.85 |
$194,778 |
D/D |
(4,324) |
12,876 |
|
11% |
|
Macdonald Brian Richard |
Chief Innovation Officer |
|
2023-06-29 |
4 |
AS |
$44.37 |
$233,509 |
D/D |
(5,100) |
17,200 |
|
2% |
|
Savage William Jacob |
Chief Medical Officer |
|
2023-06-28 |
4 |
AS |
$49.20 |
$219,114 |
D/D |
(4,384) |
15,941 |
|
-5% |
|
Bryce Joanne |
Chief Financial Officer |
|
2023-06-28 |
4 |
AS |
$49.30 |
$503,114 |
D/D |
(10,072) |
1,260 |
|
-5% |
|
Bryce Joanne |
Chief Financial Officer |
|
2023-06-28 |
4 |
OE |
$1.01 |
$7,959 |
D/D |
7,880 |
11,332 |
|
- |
|
117 Records found
|
|
Page 3 of 5 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|